miR-146a promotes the initiation and progression of melanoma by activating Notch signaling.
Bottom Line:
We show these oncogenic activities are due to miR-146a targeting the NUMB mRNA, a repressor of Notch signaling.Previous studies have shown that pre-miR-146a contains a single nucleotide polymorphism (C>G rs2910164).We find that the ability of pre-miR-146a/G to activate Notch signaling and promote oncogenesis is substantially higher than that of pre-miR-146a/C.
View Article:
PubMed Central - PubMed
Affiliation: Department of Pathology, Yale University School of Medicine, New Haven, United States.
ABSTRACT
Show MeSH
Oncogenic mutations in BRAF and NRAS occur in 70% of melanomas. In this study, we identify a microRNA, miR-146a, that is highly upregulated by oncogenic BRAF and NRAS. Expression of miR-146a increases the ability of human melanoma cells to proliferate in culture and form tumors in mice, whereas knockdown of miR-146a has the opposite effects. We show these oncogenic activities are due to miR-146a targeting the NUMB mRNA, a repressor of Notch signaling. Previous studies have shown that pre-miR-146a contains a single nucleotide polymorphism (C>G rs2910164). We find that the ability of pre-miR-146a/G to activate Notch signaling and promote oncogenesis is substantially higher than that of pre-miR-146a/C. Analysis of melanoma cell lines and matched patient samples indicates that during melanoma progression pre-miR-146a/G is enriched relative to pre-miR-146a/C, resulting from a C-to-G somatic mutation in pre-miR-146a/C. Collectively, our results reveal a central role for miR-146a in the initiation and progression of melanoma. DOI: http://dx.doi.org/10.7554/eLife.01460.001. Related in: MedlinePlus |
![]() Related In:
Results -
Collection
License getmorefigures.php?uid=PMC3927633&req=5
fig2s2: shRNA-mediated downrgulation of MYC in M14 cells inhibits the expression of MYC transcriptional target genes.qRT-PCR analysis of MYC targets CCDN1 and CDC25C in M14 cells transduced with MYC shRNA expression vectors relative to cells transduced with a non-specific (NS) shRNA vector.DOI:http://dx.doi.org/10.7554/eLife.01460.011 |
View Article: PubMed Central - PubMed
Affiliation: Department of Pathology, Yale University School of Medicine, New Haven, United States.